Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Identification of Phenolic Compounds from Nettle as New Candidate Inhibitors of Main Enzymes Responsible on Type-II Diabetes

Author(s): Bouchentouf Salim*, Ghalem Said, Nadia Kambouche and Soumaya Kress

Volume 17, Issue 2, 2020

Page: [197 - 202] Pages: 6

DOI: 10.2174/1570163815666180829094831

Price: $65

Abstract

Background: In medicinal chemistry, the discovery of small organic molecules that can be optimized and lead to a future drug capable of effectively modulating the biological activity of a therapeutic target remains a major challenge. Because of the harmful secondary effects of synthesized therapeutic molecules, the development of research has been oriented towards phytomedicines. Phenolic compounds from medicinal plants are constantly explored for new therapeutic use.

Methods: In this paper, we studied interactions between main enzymes responsible for causing type 2 diabetes mellitus (T2DM) and phenolic compounds from nettle (Urtica dioica L.) using molecular Docking with Molecular Operating Environment Software (MOE).

Results: Docking results show a common molecule (secoisolariciresinol), which may form stable complexes with depeptidyl peptidase 4 (DPP-4), alpha-amylase and beta-glucosidase with binding energy of -7.04732084 kcal/mol, -3.82946181 kcal/mol and -4.16077089 kcal/mol respectively. Besides secoisolariciresinol, other phenolic compounds give better docking score than the original co-crystallized ligand for alpha-amylase (PDB ID 5U3A) and beta-glucosidase (PDB ID 1OGS).

Conclusion: The obtained results are promising for the discovery of new alpha-amylase and betaglucosidase inhibitors. This study also confirms the folk use of nettle as antidiabetic agent.

Keywords: Nettle, phenolic compounds, alpha-amylase, beta-glucosidase, DPP-4, docking.

Graphical Abstract

[1]
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94(3): 311-21.
[http://dx.doi.org/10.1016/j.diabres.2011.10.029] [PMID: 22079683]
[2]
Misumi Y, Ikehara Y. Dipeptidyl-peptidase IV.by Handbook of Proteolytic Enzymes 3rd ed. Academic Press 2013; pp. 3374-9.
[http://dx.doi.org/10.1016/B978-0-12-382219-2.00745-6]
[3]
Bhatia Y, Mishra S, Bisaria VS. Microbial β-glucosidases: cloning, properties, and applications. Crit Rev Biotechnol 2002; 22(4): 375-407.
[http://dx.doi.org/10.1080/07388550290789568] [PMID: 12487426]
[4]
Schomburg D, Salzmann M. alpha-amylase. In: Schomburg D, Salzmann M, Eds.. Enzyme Handbook Springer-Verlag Berlin Heidelberg . 1991; pp. 1-3.
[5]
Tadera K, Minami Y, Takamatsu K, Matsuoka T. Inhibition of alpha-glucosidase and alpha-amylase by flavonoids. J Nutr Sci Vitaminol (Tokyo) 2006; 52(2): 149-53.
[http://dx.doi.org/10.3177/jnsv.52.149] [PMID: 16802696]
[6]
Mahmood N. A review of α-amylase inhibitors on weight loss and glycemic control in pathological state such as obesity and diabetes. Comp Clin Pathol 2014; 25(6): 1253-64.
[http://dx.doi.org/10.1007/s00580-014-1967-x]
[7]
Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60(11): 1454-70.
[http://dx.doi.org/10.1111/j.1742-1241.2006.01178.x] [PMID: 17073841]
[8]
Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013; 12(2): 153-75.
[http://dx.doi.org/10.1517/14740338.2013.752813] [PMID: 23241069]
[9]
Patience O, Estella U, Philip F. The search for new hypoglycemic agents from plants. Afr J Pharm Pharmacol 2014; 8(11): 292-303.
[http://dx.doi.org/10.5897/AJPP2014.3933]
[10]
Mukesh R, Namita P. Medicinal plants with antidiabetic potential - A review. Am-Eurasian J Agric Environ Sci 2013; 13(1): 81-94.
[11]
Kazi S. Use of traditional plants in diabetes mellitus: A review. Int J Pharm 2014; 4(4): 283-9.
[12]
Bamborough P, Cohen FE. Modeling protein-ligand complexes. Curr Opin Struct Biol 1996; 6(2): 236-41.
[http://dx.doi.org/10.1016/S0959-440X(96)80081-9] [PMID: 8728658]
[13]
Bernard M, Wichtl M, Anton R. Plantes thérapeutiques. Paris: Éd. Tec & Doc 2003.
[14]
Ahangarpour A, Mohammadian M, Dianat M. Antidiabetic effect of hydroalcholic urticadioica leaf extract in male rats with fructose-induced insulin resistance. Iran J Med Sci 2012; 37(3): 181-6.
[PMID: 23115450]
[15]
Tarighat esfanjani A, Namazi N, Bahrami A, Ehteshami M. Effect of hydroalcoholic extract of nettle (urtica dioica) on glycemic index and insulin resistance index in type 2 diabetic patients. Majallah-i Ghudad-i Darun/Riz va Mitabulism-i Iran 2012; 13(6): 561-8.
[16]
Kianbakht S, Khalighi-Sigaroodi F, Dabaghian FH. Improved glycemic control in patients with advanced type 2 diabetes mellitus taking Urtica dioica leaf extract: a randomized double-blind placebo-controlled clinical trial. Clin Lab 2013; 59(9-10): 1071-6.
[http://dx.doi.org/10.7754/Clin.Lab.2012.121019] [PMID: 24273930]
[17]
Hoşbaş S. Bitkisi Üzerinde Farmakognozik Araştirmalar PhD Thesis 2008.
[18]
Francišković M, Gonzalez-Pérez R, Orčić D, et al. Chemical composition and immuno-modulatory effects of urtica dioica L. (stinging nettle) Extracts. Phytother Res 2017; 31(8): 1183-91.
[http://dx.doi.org/10.1002/ptr.5836] [PMID: 28544187]
[19]
1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7: Chemical Computing Group Inc. . 2014.
[20]
Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 2004; 1(4): 337-41.
[http://dx.doi.org/10.1016/j.ddtec.2004.11.007] [PMID: 24981612]
[21]
Bouchentouf S, Allai H, Ghalem S. First study on anti-diabetic effect of rosemary and salvia by using molecular docking. J Pharm Res Int 2017; 19(4): 1-12.
[http://dx.doi.org/10.9734/JPRI/2017/37061]

Rights & Permissions Print Cite
Article Metrics
20
2
© 2024 Bentham Science Publishers | Privacy Policy